Office of the Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Office of the Director, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Immunity. 2020 Jul 14;53(1):1-5. doi: 10.1016/j.immuni.2020.06.012. Epub 2020 Jun 23.
The development, validation, and appropriate application of serological assays to detect antibodies to SARS-CoV-2 are essential to determining seroprevalence of this virus in the United States and globally and in guiding government leadership and the private sector on back-to-work policies. An interagency working group of the US Department of Health and Human Services convened a virtual workshop to identify knowledge gaps and key outstanding scientific issues and to develop strategies to fill them. Key outcomes of the workshop included recommendations for (1) advancing serology assays as a tool to better understand SARS-CoV-2 infection and (2) conducting crucial serology field studies to advance an understanding of immunity to SARS-CoV-2, leading to protection and duration of protection, including the correlation between serological test results and risk of reinfection.
开发、验证和适当应用血清学检测方法来检测针对 SARS-CoV-2 的抗体，对于确定美国和全球范围内该病毒的血清流行率，以及为政府领导和私营部门提供有关返工政策的指导至关重要。美国卫生与公众服务部的一个机构间工作组召开了一次虚拟研讨会，以确定知识差距和关键的未决科学问题，并制定解决这些问题的策略。研讨会的主要成果包括以下建议：（1）推进血清学检测作为更好地了解 SARS-CoV-2 感染的工具；（2）开展至关重要的血清学实地研究，以增进对 SARS-CoV-2 免疫力的了解，从而实现保护和保护持续时间，包括血清学检测结果与再感染风险之间的相关性。
